We combine healthcare expertise with financial, economic, and statistical analysis to advise acquirers, targets, fiduciaries, shareholders, companies, and regulators involved in bankruptcy and securities litigation.

In the context of healthcare and life sciences, Brattle values private and public healthcare companies, biopharmaceutical firms, and drug portfolios, including drugs under development. We also quantify how accounting disclosures, business or contract disputes, and generic or biosimilar entry have economically impacted the related companies.